Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity-Reference-Cited by-同舟云学术

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity

Published:2013-09-22 Issue:1 Volume:33 Page:39-47
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Takahashi Nobunori,Kojima Toshihisa,Kaneko Atsushi,Kida Daihei,Hirano Yuji,Fujibayashi Takayoshi,Yabe Yuichiro,Takagi Hideki,Oguchi Takeshi,Miyake Hiroyuki,Kato Takefumi,Fukaya Naoki,Ishikawa Hisato,Hayashi Masatoshi,Tsuboi Seiji,Kanayama Yasuhide,Kato Daizo,Funahashi Koji,Matsubara Hiroyuki,Hattori Yosuke,Hanabayashi Masahiro,Hirabara Shinya,Terabe Kenya,Yoshioka Yutaka,Ishiguro Naoki

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-013-2392-2.pdf

Reference28 articles.

1. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics R (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British society for rheumatology biologics register. Rheumatology 45(12):1558–1565. doi: 10.1093/rheumatology/kel149

2. van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, Zahora R, Pedersen R, MacPeek D, Wajdula J, Fatenejad S (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56(12):3928–3939. doi: 10.1002/art.23141

3. Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K (2009) Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol Jpn Rheum Assoc 19(5):488–492

4. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H (2008) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol Jpn Rheum Assoc 18(2):146–152. doi: 10.1007/s10165-008-0026-3

5. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70(5):755–759. doi: 10.1136/ard.2010.139725

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stairway to Heaven: Do head-to-head Trials Indicate a Need for Definite Criteria for Choosing Biologic Drugs in Rheumatoid Arthritis?;Current Rheumatology Reviews;2023-08-03

2. Scoring Model to Predict a Low Disease Activity in Elderly Rheumatoid Arthritis Patients Initially Treated with Biological Disease-modifying Antirheumatic Drugs;Internal Medicine;2021-06-15

3. Analysis of the use of a selective modulator of cosmulation of T‑lymphocytes abatacept in the treatment of rheumatoid arthritis: data from international clinical practice;Medical alphabet;2019-11-26

4. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis;Clinical Rheumatology;2019-05-17

5. Early Response of DAS28-ESR (3) Predicts Sustained Response to Tocilizumab Switched from Abatacept;Journal of St. Marianna University;2019